Literature DB >> 28630320

Δ20 IFITM2 differentially restricts X4 and R5 HIV-1.

Wan-Lin Wu1, Christopher Robert Grotefend1, Ming-Ting Tsai1, Yi-Ling Wang1, Vladimir Radic1, Hyungjin Eoh1, I-Chueh Huang2.   

Abstract

CCR5 (R5)-tropic, but not CXCR4 (X4)-tropic, HIV-1 is associated with primary HIV-1 infection and transmission. Recent studies have shown that IFN-induced transmembrane (IFITM) proteins, including IFITM1, IFITM2, and IFITM3, restrict a broad range of viruses. Here, we demonstrate that an IFITM2 isoform (Δ20 IFITM2) lacking 20 amino acids at the N terminus differentially restricts X4 and R5 HIV-1. Δ20 IFITM2 suppresses replication of X4 HIV-1 strains by inhibiting their entry. High levels of Δ20 IFITM2 expression could be detected in CD4+ T cells and in monocytes. Infection of X4 viruses in monocyte-derived macrophages and dendritic cells is enhanced upon depletion of IFITM2 isoforms. Furthermore, we also show that coreceptor use is the determining factor for differential HIV-1 restriction of Δ20 IFITM2. When we replace the C terminus of CCR5 with the C terminus of CXCR4, R5 viruses become more susceptible to Δ20 IFITM2-mediated restriction. In contrast to previous studies, our research reveals that neither X4 nor R5 HIV-1 is suppressed by IFITM2 and IFITM3. The multifactor gatekeeping model has been proposed to explain restriction of X4 viruses in the early stage of HIV-1 diseases. Our findings indicate that Δ20 IFITM2 may serve as a major contributor to this gatekeeping mechanism.

Entities:  

Keywords:  HIV; gatekeeping; interferon-inducible transmembrane protein; viral entry; Δ20 IFITM2

Mesh:

Substances:

Year:  2017        PMID: 28630320      PMCID: PMC5502592          DOI: 10.1073/pnas.1619640114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Interaction of HIV-1 and human salivary mucins.

Authors:  E J Bergey; M I Cho; B M Blumberg; M L Hammarskjöld; D Rekosh; L G Epstein; M J Levine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-10

Review 3.  Chemokine receptor CCR5: insights into structure, function, and regulation.

Authors:  Martin Oppermann
Journal:  Cell Signal       Date:  2004-11       Impact factor: 4.315

4.  Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission.

Authors:  B K Patterson; A Landay; J Andersson; C Brown; H Behbahani; D Jiyamapa; Z Burki; D Stanislawski; M A Czerniewski; P Garcia
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

5.  HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes.

Authors:  Kosuke Miyauchi; Yuri Kim; Olga Latinovic; Vladimir Morozov; Gregory B Melikyan
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

6.  Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism.

Authors:  M O McClure; M Marsh; R A Weiss
Journal:  EMBO J       Date:  1988-02       Impact factor: 11.598

7.  IFITM3 inhibits influenza A virus infection by preventing cytosolic entry.

Authors:  Eric M Feeley; Jennifer S Sims; Sinu P John; Christopher R Chin; Thomas Pertel; Li-Mei Chen; Gaurav D Gaiha; Bethany J Ryan; Ruben O Donis; Stephen J Elledge; Abraham L Brass
Journal:  PLoS Pathog       Date:  2011-10-27       Impact factor: 6.823

8.  IFITM3 polymorphism rs12252-C restricts influenza A viruses.

Authors:  David Evan Joseph Williams; Wan-Lin Wu; Christopher Robert Grotefend; Vladimir Radic; Changik Chung; Young-Hwa Chung; Michael Farzan; I-Chueh Huang
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

9.  A versatile viral system for expression and depletion of proteins in mammalian cells.

Authors:  Eric Campeau; Victoria E Ruhl; Francis Rodier; Corey L Smith; Brittany L Rahmberg; Jill O Fuss; Judith Campisi; Paul Yaswen; Priscilla K Cooper; Paul D Kaufman
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

10.  IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.

Authors:  Jingyou Yu; Minghua Li; Jordan Wilkins; Shilei Ding; Talia H Swartz; Anthony M Esposito; Yi-Min Zheng; Eric O Freed; Chen Liang; Benjamin K Chen; Shan-Lu Liu
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

View more
  12 in total

1.  Functional Mapping of Regions Involved in the Negative Imprinting of Virion Particle Infectivity and in Target Cell Protection by Interferon-Induced Transmembrane Protein 3 against HIV-1.

Authors:  Mathilde Delpeuch; Li Zhong; Romain Appourchaux; Julien Burlaud-Gaillard; Kevin Tartour; George Savidis; Abraham Brass; Lucie Etienne; Philippe Roingeard; Andrea Cimarelli
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

2.  Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Authors:  Xuesen Zhao; Mohit Sehgal; Zhifei Hou; Junjun Cheng; Sainan Shu; Shuo Wu; Fang Guo; Sylvain J Le Marchand; Hanxin Lin; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

Review 3.  HIV-1 entry: Duels between Env and host antiviral transmembrane proteins on the surface of virus particles.

Authors:  Tomoyuki Murakami; Akira Ono
Journal:  Curr Opin Virol       Date:  2021-08-12       Impact factor: 7.121

4.  The Role of IFITM Proteins in Tick-Borne Encephalitis Virus Infection.

Authors:  Alicja M Chmielewska; Maria Gómez-Herranz; Paulina Gach; Marta Nekulova; Małgorzata A Bagnucka; Andrea D Lipińska; Michał Rychłowski; Weronika Hoffmann; Ewelina Król; Borivoj Vojtesek; Richard D Sloan; Krystyna Bieńkowska-Szewczyk; Ted Hupp; Kathryn Ball
Journal:  J Virol       Date:  2021-10-06       Impact factor: 6.549

5.  HIV envelope tail truncation confers resistance to SERINC5 restriction.

Authors:  Tafhima Haider; Xenia Snetkov; Clare Jolly
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 12.779

Review 6.  More than meets the I: the diverse antiviral and cellular functions of interferon-induced transmembrane proteins.

Authors:  Guoli Shi; Olivier Schwartz; Alex A Compton
Journal:  Retrovirology       Date:  2017-11-21       Impact factor: 4.602

Review 7.  Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane.

Authors:  Toshana L Foster; Suzanne Pickering; Stuart J D Neil
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

8.  Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.

Authors:  Kevin Tartour; Xuan-Nhi Nguyen; Romain Appourchaux; Sonia Assil; Véronique Barateau; Louis-Marie Bloyet; Julien Burlaud Gaillard; Marie-Pierre Confort; Beatriz Escudero-Perez; Henri Gruffat; Saw See Hong; Marie Moroso; Olivier Reynard; Stéphanie Reynard; Elodie Decembre; Najate Ftaich; Axel Rossi; Nannan Wu; Frédérick Arnaud; Sylvain Baize; Marlène Dreux; Denis Gerlier; Glaucia Paranhos-Baccala; Viktor Volchkov; Philippe Roingeard; Andrea Cimarelli
Journal:  PLoS Pathog       Date:  2017-09-28       Impact factor: 6.823

9.  mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3.

Authors:  Guoli Shi; Stosh Ozog; Bruce E Torbett; Alex A Compton
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

10.  The Inhibition of HIV-1 Entry Imposed by Interferon Inducible Transmembrane Proteins Is Independent of Co-Receptor Usage.

Authors:  Jingyou Yu; Shan-Lu Liu
Journal:  Viruses       Date:  2018-08-07       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.